Please Wait
Applying Filters...
menu
    • menu
    Virupaksha-PSE
    News
    Virupaksha Organics agreed to acquire 42.29% stake in Oxygenta

    30 Sep 2024

    // BSEINDIA

    Ipsen's ADC push leads to $1B deal for preclinical Simcere drug

    24 Dec 2025

    // GLOBENEWSWIRE

    Granules India Gets USFDA Tentative Approval For Amphetamine ER

    24 Dec 2025

    // PRESS RELEASE

    Data Compilation
    #PharmaFlow

    Read More

    Contact Supplier

    Website

    BIO Partnering at JPM

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/cdmo-activity-tracker-lupin-s-cdmo-commissions-oncology-block-in-india-cambrex-axplora-hovione-expand-operations
    Menu

    Oxygenta Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    INTERMEDIATES

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Virupaksha Organics agreed to acquire 42.29% stake in Oxygenta
    Virupaksha Organics agreed to acquire 42.29% stake in Oxygenta

    30 Sep 2024

    // BSEINDIA

    https://www.bseindia.com/xml-data/corpfiling/AttachHis/1C45CF51-65B3-4DE7-B64C-CE5E996BBAD7-191527.pdf

    BSEINDIA
    30 Sep 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.